RAMSES

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

Dave Bloom - 2018/01/08

The company announces their timeline for continued progress toward an FDA approved standardized therapy.

Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...

Dave Bloom - 2017/05/17

First of 440 patients enrolled in study of AR101.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

Tag: RAMSES

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...